The Chemkart India IPO marks the public debut of a leading distributor and processor of food and health ingredients, incorporated in 2015 and headquartered in Mumbai. Chemkart India specializes in sourcing, blending, and packaging high-quality amino acids, vitamins, herbal extracts, and nutraceuticals for B2B clients across the supplements, sports nutrition, and health sectors. The company has demonstrated impressive growth, with revenue rising 55% and profit after tax up 67% between FY24 and FY25. The Chemkart India IPO aims to fund new manufacturing capacity, reduce debt, and support future expansion.
₹3
₹248
₹250.00
Expert Opinions
The Chemkart India IPO is generating positive market sentiment, driven by the company’s rapid revenue and profit growth, which outpaces industry averages. Chemkart’s strengths include a diversified B2B product range, robust supply chain, and a modern processing facility, enabling it to serve the expanding nutraceutical and health ingredients market. For FY 2025, the Chemkart India IPO posts a Return on Equity (ROE) of 59%, Return on Capital Employed (ROCE) of 49%, and Net Asset Value (NAV) of ₹56.10, highlighting strong operational efficiency and capital management.
However, risks remain in product and customer concentration, as well as underutilization of high-margin, value-added offerings. From a long-term perspective, Chemkart’s growth prospects are promising if it can scale its formulation business and diversify its portfolio, making it appealing for investors seeking exposure to India’s fast-growing nutraceutical sector.
Investor Considerations
Investors considering the Chemkart India IPO should note the company’s robust fundamentals, with revenue rising 55% and profit after tax up 67% between FY24 and FY25, supported by a CAGR of 24.39% over two years. The nutraceutical sector outlook remains positive, driven by growing demand for health and wellness products in India. For FY 2025, the Chemkart India IPO is valued at a Price to Book Value of 8.12, EBITDA margin of 16.12%, and a conservative Debt/Equity ratio of 0.32, reflecting operational efficiency and manageable leverage.
Growth prospects are strong due to product diversification and a modern processing facility, but risks include reliance on a few suppliers, high exposure to Chinese imports, and customer concentration. While short-term gains may be possible, the Chemkart India IPO is best suited for long-term investors seeking exposure to India’s expanding nutraceutical industry and willing to monitor supply chain and compliance risks.
| Date | GMP | Trend |
|---|---|---|
| 13 Jul 2025 15.27 | ₹3 | Up |
| 12 Jul 2025 15.59 | ₹00 | --- |
| 11 Jul 2025 10.14 | ₹00 | --- |
| 10 Jul 2025 10.30 | ₹00 | --- |
| 09 Jul 2025 10.51 | ₹00 | --- |
| 07 Jul 2025 10.49 | ₹00 | --- |
| 06 Jul 2025 17.08 | ₹00 | --- |
| 05 Jul 2025 10.28 | ₹00 | --- |
| 04 Jul 2025 10.39 | ₹00 | --- |
FAQs
The Grey Market Premium showed poor accuracy in predicting Chemkart India IPO’s listing performance. Despite a final GMP of ₹3, indicating a marginal premium of 1.21% over the issue price of ₹248, the stock listed almost flat at ₹250, delivering a negligible gain of just 0.81%. With a prediction error of 0.40%, the GMP correctly suggested a positive direction but failed to reflect the minimal actual gain, highlighting its weak predictive value in this case.
Chemkart India IPO Current GMP is ₹3.
Chemkart India IPO Expected Returns is 1.21%.
Chemkart India IPO estimated listing price is ₹251.